> Details

Tran, Thi Nhu Mai; May, Bruce Pearson; Ung, Trong Thuan; Nguyen, Mai Khoi; Nguyen, Thi Thuy Trang; Dinh, Van Long; Doan, Chinh Chung; Tran, The Vinh; Khong, Hiep; Nguyen, Thi Thanh Truc; Hua, Hoang Quoc Huy; Nguyen, Viet Anh; Ha, Tan Phat; Phan, Dang Luu; Nguyen, Truong An; Bui, Thi Ngoc; Tu, Tieu My; Nguyen, Thi Theo; Le, Thi Thuy Hang; Dong, Thi Lan; Huynh, Trong Hieu; Ho, Phien Huong; Le, Nguyen Thanh Thao; Truong, Cong Thao; [...]

Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19
  • Contributor: Tran, Thi Nhu Mai; May, Bruce Pearson; Ung, Trong Thuan; Nguyen, Mai Khoi; Nguyen, Thi Thuy Trang; Dinh, Van Long; Doan, Chinh Chung; Tran, The Vinh; Khong, Hiep; Nguyen, Thi Thanh Truc; Hua, Hoang Quoc Huy; Nguyen, Viet Anh; Ha, Tan Phat; Phan, Dang Luu; Nguyen, Truong An; Bui, Thi Ngoc; Tu, Tieu My; Nguyen, Thi Theo; Le, Thi Thuy Hang; Dong, Thi Lan; Huynh, Trong Hieu; Ho, Phien Huong; Le, Nguyen Thanh Thao; Truong, Cong Thao; [...]
  • imprint: Frontiers Media SA, 2021
  • Published in: Frontiers in Immunology
  • Language: Not determined
  • DOI: 10.3389/fimmu.2021.766112
  • ISSN: 1664-3224
  • Origination:
  • Footnote:
  • Description: <jats:p>The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health concern. The development of vaccines with high immunogenicity and safety is crucial for controlling the global COVID-19 pandemic and preventing further illness and fatalities. Here, we report the development of a SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the spike (S) protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG and neutralizing antibodies in three animal models: BALB/c mouse, Syrian hamster, and a non-human primate (<jats:italic>Macaca leonina</jats:italic>). In addition, a viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. Nanocovax did not induce any adverse effects in mice (<jats:italic>Mus musculus</jats:italic> var. albino) and rats (<jats:italic>Rattus norvegicus</jats:italic>). These preclinical results indicate that Nanocovax is safe and effective.</jats:p>
  • Access State: Open Access